Wang W, Chen Q, Zhang F, et al. - Researchers examined the impact of spironolactone as an aldosterone (ALD) antagonist on the short-term as well as long-term recurrence of atrial fibrillation (AF) post-radiofrequency ablation (RFA). Participants were 203 patients in total, with 102 comprising the spironolactone therapy group (Group PVI/SP) and 101 patients were included in the control group (Group PVI alone). Post-treatment, significantly lower levels of angiotensin II (AngII), ALD, and N-terminal of B-type natriuretic peptide as well as the size of the left atrium, was detected in Group PVI/SP vs Group PVI alone. Higher cumulative AF-free survival rate was observed in Group PVI/SP vs in Group PVI alone following treatment. In RFA plus spironolactone treatment, spironolactone was shown to have the ability to directly antagonize the impacts of ALD and AngII as well as AF recurrence and improve left ventricular function.